Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial.
Adding iberdomide to standard myeloma therapy improved sustained cancer remission rates, offering hope for patients whose disease had resisted prior treatments.
BACKGROUND: Iberdomide, a cereblon E3 ligase modulator with enhanced antimyeloma and immunostimulatory activity compared with immunomodulatory drugs, has shown clinical activity in relapsed or refractory multiple myeloma... Eligible participants were adults (aged ≥18 years) with relapsed or refractory multiple myeloma, who had undergone one to two previous lines of therapy, had an Eastern Cooperative Oncology Group performance-status score ...
What the study was
- Study design
- Randomized study
- Population
- patients
- Category
- Other
- Maturity
- Exploratory
- Journal
- The Lancet. Oncology
Why it surfaced
Score 7/10 [PROMISING_PRELIMINARY]: Randomized study (Journal Article) matched 'Hematologic malignancies'. Components — novelty:1/3, relevance:2/3, design:2/2, population:2/2. Confidence: high. Conservative scoring applied per v1.3 rubric.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.